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The effect of marine n-3 polyunsaturated
fatty acids on cardiac autonomic and
hemodynamic function in patients with
psoriatic arthritis: a randomised, double-
blind, placebo-controlled trial
Salome Kristensen1* , Erik Berg Schmidt2, Annette Schlemmer1, Claus Rasmussen3, Esther Lindgreen1,
Martin Berg Johansen4 and Jeppe Hagstrup Christensen5
Abstract
Background: The aim of this study was to investigate the effect of marine n-3 polyunsaturated fatty acids (PUFA)
on cardiac autonomic function and vascular function in patients with psoriatic arthritis.
Methods: The study was conducted as a randomized, double-blind, placebo-controlled trial, where 145 patients
with psoriatic arthritis were supplemented with 3 g of n-3 PUFA or olive oil (control) daily for 24 weeks. Blood
pressure, heart rate, heart rate variability (HRV), central blood pressure, pulse wave velocity (PWV) and fatty acid
composition of granulocytes, were determined at baseline and after supplementation.
Results: At baseline we found a significant difference in the mean of all normal RR intervals (inverse of heart rate, vary
from beat to beat) when comparing subjects with the highest vs the lowest fish intake (p= 0.03). After supplementation for
24 weeks there was a trend towards an increase in RR (p= 0.13) and decrease in heart rate (p= 0.12) comparing the n-3
PUFA group with the control group. However, per-protocol analysis showed significantly increased RR (p= 0.01) and
lowered heart rate (p= 0.01) in the n-3 PUFA supplemented patients compared with controls. Blood pressure, PWV and
Central blood pressure did not change after supplementation with n-3 PUFA. Adjustment for disease activity and
conventional cardiovascular risk factors did not change the results.
Conclusions: Marine n-3 PUFA increased RR intervals in patients with psoriatic arthritis which may suggest a protective
effect of n-3 PUFA against cardiovascular disease in this population.
Trial registration: Clinicaltrials.gov Identifier: NCT01818804
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Background
Psoriatic arthritis (PsA) is a chronic inflammatory joint
disease occurring in 6–39% of patients with psoriasis
and with a prevalence in the general population of
approximately 0.2% [1–3].
Patients with inflammatory diseases such as rheuma-
toid arthritis and systemic lupus erythematosus are at an
increased risk of cardiovascular disease (CVD) [4] and
recent observational studies indicate that PsA patients
also have an increased cardiovascular mortality and
morbidity [5, 6]. Accelerated atherosclerosis due to in-
flammation, and autonomic dysfunction can both play a
role in the pathogenesis of CVD in patients with PsA in
addition to conventional risk factors for CVD such as
smoking, hypertension, hypercholesterolemia and diabetes
mellitus [7].
Several studies have indicated that chronic inflamma-
tion may impair autonomic cardiac regulation leading to
a decrease in heart rate variability (HRV) [8, 9]. A low
HRV has been identified as an independent predictor of
coronary heart disease [10], as well as malignant ven-
tricular arrhythmias and sudden cardiac death [11–15].
Also, arterial stiffness has been recognised as an inde-
pendent predictor of CVD [16, 17]. Studies using non-
invasive methods such as pulse wave velocity (PWV) for
evaluation of CVD risk have revealed increased arterial
stiffness in patients with PsA [18–20].
A beneficial effect of marine n-3 polyunsaturated fatty
acids (PUFA) on CVD has been suggested from several
epidemiological studies, experimental data and clinical
trials [21]. Interestingly, the major marine n-3 PUFA, ei-
cosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic
acid (DHA; 22:6n-3), have been shown to have anti-
inflammatory effects [22] and beneficial effects on blood
pressure (BP) and cardiac autonomic function [23, 24].
The present study aimed to examine whether supple-
mentation with a moderate to high (3 g) daily dose of
marine n-3 PUFA for 24 weeks had a beneficial effect on
cardiac autonomic and hemodynamic function repre-
sented by BP, heart rate (HR), HRV, PWV and central BP
in patients with PsA.
Methods
Study design
The study was designed as a randomized, double-blind,
placebo-controlled trial. The patients were randomly
assigned in blocks of five by a computer-generated block
sequence. For 24 weeks patients were assigned to daily
intake of six capsules containing either 3 g of n-3 PUFA
(50% EPA and 50% DHA) or 3 g of olive oil (approxi-
mately 80% of oleic acid and 20% linoleic acid). Investi-
gators, patients and research staff were blinded to the
supplementation codes. Patients were asked to maintain
their usual diet during the entire study. The study was
conducted in a 2 year period between 2013 and 2015.
Clinical assessment, blood samples, HRV and PWV were
carried out at baseline and after 24 weeks. The study was
conducted in accordance with the Declaration of Helsinki
and registered at ClinicalTrials.gov (NCT01818804).
Furthermore the study was monitored by Good Clinical
Practice (GCP) inspectors and the GCP ethical and scien-
tific quality requirements were followed.
Subjects
Patients with PsA defined by Classification criteria for
psoriatic arthritis (CASPAR) [25] were enrolled from the
Department of Rheumatology, Aalborg University Hos-
pital and Department of Rheumatology, Vendsyssel Hos-
pital, in Denmark. The inclusion criteria were PsA in
adults above 18 years of age with any disease activity
while exclusion criteria were documented known cardiac
arrhythmias, treatment with biological drugs, or treat-
ment with oral corticosteroids. Patients using fish oil
supplements (n = 2) underwent a wash-out period of at
least 8 weeks before inclusion.
Compliance was assessed by counting capsules during
the last visit. Patients were defined as non-compliant if
missing >15% of capsules and these patients were not in-
cluded in the per-protocol analysis.
All participants gave their written informed consent
and the regional ethics committee of Northern Region
DK, approved the study (reference number N20120076).
Clinical assessment
At baseline, duration of PsA, medical history, smoking
habits and diets were obtained. Medical history of dia-
betes mellitus, hypertension and dyslipidemia was
assessed and was defined as present if the patient re-
ceived dietary or medical therapy for the condition. A
food questionnaire was used to assess patients’ fish con-
sumption at lunch and dinner. A score for fish intake
was given according to the following: never eating fish =
1; eating fish once a month =2; eating fish two to three
times a month = 3; eating fish once a week = 4; eating
fish two to three times a week = 5; and eating fish at
least once daily = 6.
At both visits conventional cardiovascular risk factors
such as smoking habits, BP, body mass index (BMI) and
waist to hip ratio (WHR) were assessed. Additionally, a
clinical evaluation was performed, consisting of 68 ten-
der joint count, 66 swollen joint count, disease activity
score (DAS66/68) and psoriatic skin area involvement
(PASI).
Blood samples
Blood samples were taken non-fasting for assessment of
fatty acid composition of granulocytes and routine la-
boratory evaluation including plasma levels of C-reactive
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protein (CRP). Granulocytes were isolated from whole
blood and their fatty acid composition were determined
by gas chromatography with a Chrompack CP-9002 gas
chromatograph (Varian, Middelberg, The Netherlands)
and expressed as weight percent (wt %) of total fatty
acids. The following fatty acids were evaluated in the
further analyses: eicosapentaenoic acid (EPA; 20:5n-3),
docosahexaenoic acid (DHA; 22:6n-3), docosapentaenoic
acid (DPA; 22:5n-3), arachidonic acid (AA; 20:4n-6),
oleic acid (18:1n-9), linoleic acid (LA; 18:2n-6), palmitic
acid (16:0) and stearic acid (18:0).
HRV
Five min. HRV recordings were obtained with SphygmoCor
Technology (SphygmoCor, Software version 8.2; AtCor
Medical, Sydney, NSW, Australia) in each patient. HRV was
recorded according to current recommendations [26] with
measurements obtained in the morning hours after resting
for 15 min in a room with a constant temperature of 20 °C.
Patients were instructed not to smoke and avoid alcohol
and caffeine-containing beverages within 12 h prior to inves-
tigation. A trained technician blinded to the type of supple-
ment performed these analyses. The patients were in a
supine position (resting) for 10 min, breathing spontan-
eously without talking. HRV were analysed in the time-
domain and the following variables were obtained:
 HR: heart rate
 RR: mean of all normal RR intervals during the
5 min recording (inverse of heart rate, vary from
beat to beat)
 SDNN: standard deviation of all normal RR intervals
in the 5 min recording
 SDNNindex: mean of the standard deviation of all
the normal RR intervals
 pNN50: percentage of successive RR-interval differ-
ences > 50 ms
 RMSSD: square root of the mean of the sum of the
squares of differences between adjacent intervals
PWV
PWV and pulse wave analysis were performed non-
invasively with the Sphygmocor system (AtCor Medical,
Sydney, NSW, Australia), as described previously [27] and
according to international recommendations [28]. All
measurements were made in duplicate by a single trained
operator and the mean of the two values was used in the
analysis. Carotid-radial and carotid-femoral PVW were
measured using arterial tonometry. The measurements
were obtained under the same conditions as described
under HRV. The patients were in a supine position and all
measurements were performed on the right side extrem-
ities. The surface distance was measured with a tape
measure as a straight line from the suprasternal notch to
the carotid location (proximal pulse) and subtracted the
distance from the suprasternal notch to the radial or
femoral location (distal pulse) [29, 30]. The pressure wave
transit time was determined as the time between the R-
wave of the ECG and the proximal pulse subtracted from
the time between the R-wave of the ECG and the distal
pulse. PWV was subsequently calculated by dividing the
surface distance by the pressure wave transit time.
The central BP was estimated using the SphygmoCor®
device. After 10 min of rest in the supine position,
brachial BP was measured three times at 2-min intervals
on the left arm with an automatic Microlife® device, and
the last measurement was taken as representative of bra-
chial artery BP. Hereafter, radial artery pressure wave-
forms of the right arm were sampled. Using the validated
generalized transfer function, central BP was estimated
using brachial systolic and diastolic BP [31, 32]. Aortic
augmentation index (AIx) was standardized to a HR of 75
beat per minute to minimize the effect of HR.
Statistical Analysis
All statistical analyses were performed using Stata: Re-
lease 13 (StataCorp LP, TX, US). HRV measurements
were primary outcome and PWV measurements second-
ary outcome.
We hypothesized that intervention with n-3 PUFA
would increase RR. Based on previous literature [33, 34]
and to achieve α = 0.05 and 1-β = 0.80 we needed a sam-
ple size with 63 subjects in each group.
The score for fish intake at baseline was grouped ac-
cording to tertiles. The content of DHA and EPA in
granulocytes were also grouped according to tertiles.
The difference in the continuous outcomes between
baseline and 24 weeks after randomization was com-
pared between the two treatment groups in a one-way
analysis of variance (ANOVA). Equality of variances be-
tween the treatment groups was assessed using Bartlett’s
test. Due to the potential for confounding after the ran-
dom treatment assignment an analysis of covariance
(ANCOVA) was performed. Prior to this analysis a
check for collinearity between the covariates was per-
formed and the model was modified accordingly. In this
model equality of variances was assessed using Levene’s
test. All analyses were performed both as intention to treat
and per-protocol (patients who completed the entire clin-
ical trial according to the protocol and consumed > 85% of
the assigned supplement) analyses. The ANCOVA
analyses were controlled for age, sex, smoking status,
presence or absence of diabetes mellitus, hypertension
and hypercholesterolemia, use of nonsteroidal anti-
inflammatory drugs (NSAID) and DAS66/68.
Differences were considered significant with a p-value
of <0.05 (two-tailed).
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Results
A total of 145 patients were enrolled and 133 patients
(92%) completed the study. Seven patients in the control
arm and five patients in the n-3 PUFA arm withdrew
from the study before last visit and five patients were
excluded because of insufficient HRV recordings at base-
line. Ten patients in the n-3 PUFA group and four in
the control group were defined as noncompliant accord-
ing to the number of capsules returned and were not in-
cluded in the per-protocol analysis. Figure 1 shows the
study flow diagram.
The n-3 PUFA and the control groups were compar-
able regarding baseline characteristics, apart from num-
ber of current smokers and number of patients with
known hypercholesterolemia (Table 1). Thus, adjust-
ments were made for these to parameters in the final
analysis. Patients excluded from final analysis did not
differ from patients eligible for final analysis in regard to
baseline characteristics (data not shown). Nine
participants in the n-3 PUFA supplemented group and
six participants in the control group reported mild
gastrointestinal adverse effect. In 13 of these participants
the side effects was avoided by changing the intake of
capsules from six capsules once daily to two capsules
three times daily. The remaining two participants were
in the placebo group and dropped out because of nausea
and mild diarrhea.
Baseline analyses
Patients with the highest fish intake had a significantly
higher RR than patients with the lowest intake (p = 0.03).
Also, patients in the tertile with the highest content of
DHA in granulocytes had the highest RR (p = 0.04)
whereas the content of EPA in granulocytes was not as-
sociated with RR. The associations between dietary fish
intake and RR seemed to be dose dependent (Figs. 2 and
3). There were no association between DAS66/68 and
RR at baseline.
Intervention analyses
The group randomized to n-3 PUFA had a significant in-
crease in total content of n-3 PUFA (DHA + EPA +
DPA), DHA and EPA in granulocytes from baseline to
study end compared to the control group. There were
Fig. 1 Flow diagram of the study participants
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also a significant decrease in the granulocyte content of
AA and LA in the n-3 PUFA supplemented group com-
pared to control group (Table 2).
Intention to treat analysis
After supplementation for 24 weeks there was a trend
towards an increase in RR (p = 0.06) and a decrease in
HR (p = 0.12) comparing the n-3 PUFA group with the
control group (Table 3).
There were no significant change in BP, PWV or cen-
tral BP in the n-3 PUFA supplemented group or between
the n-3 PUFA and control group. Adjustment for con-
ventional CVD risk factors and DAS66/68 did not affect
the results.
DAS66/68 and CRP were not associated with HRV or
PWV.
Per-protocol analysis
Analyses of outcomes after 24 weeks revealed a signifi-
cant increase in RR and decrease in HR in the fish oil
supplemented group and there was a significant differ-
ence in changes in RR (p = 0.03) and HR (0.02) between
the n-3 PUFA and control group (Table 4). In contrast,
there were no significant change in BP, PWV or central
BPs in the n-3 PUFA supplemented group or between
the n-3 PUFA and control group. Adjustment for con-
ventional CVD risk factors and DAS66/68 did not
change the results (Table 5).
Discussion
With 145 participants and only 8% not completing, this
study is the largest investigation of the effect of marine
n-3 PUFA on cardiovascular function in patients with
PsA. We found that supplementation with 3 g n-3 PUFA
daily for 24 weeks had a beneficial effect on autonomic
control of the heart in PsA patients by decreasing heart
rate and increasing RR interval.
At baseline we found a significantly higher RR in the
patients with the highest fish intake. Baseline analysis
also showed that the content of DHA in granulocytes
was positively associated with RR. These associations
seemed to be dose dependent and the results suggest
beneficial effect of dietary fish consumption on the car-
diac autonomic tone in patients with PsA.
After intervention for 24 weeks there was a significant
shift in the PUFA composition in the active group with
an increase in the granulocyte content of n-3 PUFA and
a decrease in content of AA and LA. In the intention to
treat analysis there was a trend towards increased RR
and thereby a reciprocal lowering of HR. However, the
per-protocol analysis revealed a significant increase in
RR and decrease in HR in the n-3 PUFA supplemented
group.
HRV is considered a useful and reliable measurement
of cardiac autonomic tone [35]. A depressed HRV indi-
cates an increased cardiovascular risk in the general
population [11] and in patients with known CVD [36].
Evidence also suggests that HRV improves with fish con-
sumption and intervention with n-3 PUFA [37]. The
positive association between fish intake and RR at base-
line and the increase in RR after intervention with n-3
PUFA found in this study of patients with PsA is in line
with previous studies of other high-risk patients and
healthy subjects [38]. The effect of n-3 PUFA on HR in
our study is also consistent with previous data showing
that n-3 PUFA reduces resting HR [39, 40], an important
risk marker for cardiovascular disease [41]. As a
surrogate marker for cardiac autonomic tone, HRV can
indicate changes mediated by n-3 PUFA at the level of
cardiac efferent stimuli [42, 43]. Interestingly, in our
study baseline content of DHA but not EPA in granulo-
cytes was positively associated with RR, which is consist-
ent with findings of previous studies [44, 45]. DHA is
most abundant in the heart, brain and nervous system
membrane lipids [46] and therefore might be more influ-
ential regarding effects on cardiac autonomic function.
Table 1 Baseline demographics, biochemical and hemodynamic








Mean age 53.2 (11.4) 50.7 (11.5) 52.0 (11.5)
Sex
- Female 40 (55.6) 43 (60.6) 83 (58.0)
- Male 32 (44.4) 28 (39.4) 60 (42.0)
Smoking
- Non-smoker 36 (50.0) 41 (57.7) 77 (53.8)
- Former smoker 27 (37.5) 14 (19.7) 41 (28.7)
- Current smoker 9 (12.5) 16 (22.5) 25 (17.5)
Documented coronary
heart disease
4 (5.6) 4 (5.6) 8 (5.6)
Hypertension 21 (29.2) 20 (28.2) 41 (28.7)
Hypercholesterolemia 18 (25.0) 11 (15.5) 29 (20.3)
NSAID use 40 (55.6) 32 (45.1) 72 (50.3)
Outcomes Systolic BP, mmHg 138 (18) 134 (19) 136 (19)
Diastolic BP, mmHg 83 (11) 82 (12) 82 (12)
Hip and waste ratio 1.1 (0.1) 1.2 (0.1) 1.1 (0.1)
Body Mass Index 28.6 (5.7) 28.0 (5.0) 28.3 (5.4)
Disease Activity Score 2.5 (0.9) 2.7 (0.9) 2.6 (0.9)
CRP mg/l 4.6 (4.2) 6.1 (7.7) 5.3 (6.2)
PASI 2.2 (3.0) 2.3 (4.0) 2.3 (3.5)
Total cholesterol, mmol/l 5.0 (1.0) 4.8 (0.8) 4.9 (0.9)
Data are given as mean (sd) or n (%) as appropriate
N non-missing values, BP Blood pressure
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Interactions between the autonomic nervous system
and the immune system have been reviewed recently
and direct autonomic innervation and non-synaptic
communication with lymphoid organs has been shown
[47]. Abnormalities in the autonomic nervous system as
well as cardiovascular autonomic dysfunction has been
reported in patients with inflammatory rheumatic dis-
eases [48]. A few studies have investigated HRV in PsA
and demonstrated attenuated HRV. In a study with 38
patients with PsA and 25 healthy controls using 5-min
HRV Gaydukova et al. [49] found that SDNN was
65.1 ms and pNN50 12.9% in the PsA patients whereas
in healthy controls SDNN and pNN50 were higher
(83.2 ms and 20.6%, respectively). Proietti et al. [50] also
used short-term HRV in 26 patients with psoriasis and
27 healthy controls and found a significant difference in
RMSDD between patients with psoriasis (39.4 ms) and
the controls (53.2 ms). Our results revealed a baseline
SDNN of 50 ms, pNN50 of 13%, and RMSSD of 38 ms,
















1st tertile 2nd tertile 3rd tertile
Baseline DHA
Fig. 3 The relation between baseline RR (ms) and content of DHA in granulocytes presented in tertiles. Footnote: HRV: Heart Rate
Variability; RR: Mean of all normal RR-intervals in HRV recording; DHA: docosahexaenoic acid; *: Significant difference in RR between the


















1st tertile 2nd tertile 3rd tertile
Baseline fish intake
Fig. 2 The relation between baseline RR (ms) and fish intake presented in tertiles. Footnote: RR: Mean of all normal RR-intervals in HRV recording;
*: Significant difference in RR between the lower and the upper tertile
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A likely explanation for a low HRV in PsA is the
presence of systemic inflammation leading to a de-
creased parasympathetic regulation of cardiac auto-
nomic tone [51, 52]. In this study, DAS66/68 and
CRP were not associated with HRV or PWV. How-
ever, DAS and CRP may be a more important marker
of disease activity in patients with RA [53] than in
patients with PsA [47, 54, 55].
In a small study with 20 patients with PsA, Syngle et
al. observed improvement in autonomic dysfunction
after treatment with different synthetic DMARDs over
12 weeks [33]. However, no treatment strategy for
cardiac autonomic dysfunction in PsA has yet been dem-
onstrated. Thus, the possible beneficial effect of n-3
PUFA found in our study may be of importance in the
approach towards an improved cardiac autonomic func-
tion in PsA.
n-3 PUFA is known to have a mildly antihypertensive
effect [56]. Furthermore, studies and a meta-analysis of
randomized and controlled human clinical trials examin-
ing the effect of n-3 PUFA on arterial stiffness has
shown a reduction in arterial stiffness after treatment
with less than 4 g/d of n-3 PUFA in populations with
hypertension, diabetes mellitus, dyslipidemia, metabolic
syndrome and obesity [57, 58].
In our study we were unable to demonstrate any
changes in BP, PWV, central BP and AIx measurements.
However, in most of the previous studies arterial
Table 3 Intention to treat data with no adjustments
n-3 PUFA (n = 68) Control (n = 60)
Baseline Week 24 Difference (CI) Baseline Week 24 Difference (CI) P
Heart rate, min−1 63.83 63.29 −0.61 (−1.92; 0.70) 63.39 64.38 0.96 (−0.55; 2.47) 0.12
RR, ms 956.55 969.94 13.38 (−5.06; 31.83) 964.02 950.53 −13.48 (−35; − 8.69) 0.06
PNN50 % 10.68 11.29 0.62 (−3.25; 4.48) 15.83 14.37 −1.46 (−4.76; 1.84) 0.42
SDNN ms 49.37 48.12 −1.24 (−8.46; 5.97) 49.71 47.41 −2.30 (−6.79; 2.20) 0.81
RMSSD ms 36.59 37.58 0.99 (−7.13; 9.12) 39.84 39.15 −0.69 (−6.23; 4.85) 0.73
Peripheral systolic BP mmHg 138.20 134.53 −3.67 (−6.69; −0.65) 134.41 133.18 −1.23 (−4.59; 2.14) 0.28
Peripheral diastolic BP mmHg 82.61 81.82 −0.79 (−2.35; 0.77) 82.36 80.92 −1.44 (−3.26; 0.39) 0.59
PWV m/s 7.80 7.81 0.01 (−0.44; 0.46) 7.40 7.48 0.08 (−0.33; 0.49) 0.82
Central systolic BP mmHg 114.82 112.24 −2.58 (−4.84; −0.32) 113.29 111.38 −1.91 (−4.77; 0.95) 0.71
Central diastolic BP
mmHg
96.04 93.76 −2.28 (−4.10; −0.47) 95.45 94.17 −1.29 (−3.51; 0.94) 0.49
PWA AIx 26.42 27.54 1.12 (−0.56; 2.80) 26.97 25.82 −1.15 (−2.78; 0.47) 0.05
Outcomes presented as means with 95% confidence intervals at baseline and after 24 weeks of supplement for both groups
CI Confidence Interval, P P for difference between the two groups of supplement, HRV Heart rate variability, PWV Pulse wave velocity, BP blood pressure, AIx
central Augmentation Index
Table 2 Content of fatty acids in granulocytes presented as means with 95% confidence intervals at baseline and after 24 weeks of
supplementation for both groups
n-3 PUFA (n = 68) Control (n = 65)
Baseline Week 24 Difference (CI) Baseline Week 24 Difference (CI) P
Palmitic acid (16:0) wt.% 12.32 12.40 0.08 (−0.04 - 0.21) 12.38 12.37 −0.00 (−0.12 - 0.12) 0.33
Stearic acid (18:0) wt % 17.36 17.35 −0.01 (−0.12 - 0.11) 17.41 17.30 −0.11 (−0.24 - 0.01) 0.20
Oleic acid (18:1n-9) wt.% 32.90 33.21 0.30 (0.03; 0.57) 32.97 33.44 0.47 (0.24; 0.70) 0.35
Linoleic acid (18:2n-6) wt. % 9.12 8.62 −0.50 (−0.80; −0.21) 9.32 9.21 −0.11 (−0.26; 0.05) 0.02
AA (20:4n-6) wt % 13.05 11.44 −1.61 (−1.84; −1.38) 13.01 12.80 −0.20 (−0.37; −0.04) <0.01
Total n-6 wt % 22.17 20.05 −2.12 (−2.47 - -1.76) 22.32 22.01 −0.31 (−0.51 - -0.11) <0.01
EPA wt % 0.60 1.99 1.40 (1.24; 1.56) 0.53 0.50 −0.03 (−0.08; 0.02) <0.01
DPA wt % 1.58 2.61 1.03 (0.86; 1.21) 1.46 1.42 −0.04 (−0.10; 0.02) <0.01
DHA wt % 1.21 2.10 0.89 (0.77; 1.00) 1.14 1.11 −0.02 (−0.07; 0.02) <0.01
Total n-3 PUFA (DHA+ EPA + DPA) wt % 3.39 6.71 3.32 (2.92; 3.71) 3.13 3.03 −0.10 (−0.22; 0.03) <0.01
AA arachidonic acid, DHA docosahexaenoic acid, EPA eicosapentaenoic acid, DPA docosapentaenoic acid, wt. % weight percent, P P for the difference between the
two groups of supplement
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stiffness was not assessed with carotid-femoral PWV
(regarded as “golden standard”) as in our study. Supple-
mentation with n-3-PUFA for 24 weeks might be too
short a period to observe changes and modulation in the
vessels measured by PWV. Patients in this study had a
low mean disease activity score of 2.6 (sd = 0.9) at base-
line and 75% of the patients received disease-modifying
antirheumatic drugs. Thus, we investigated a patient
group in remission and results may not apply to patients
with a more severely disease activity. In other chronic
inflammatory diseases, such as RA and systemic vascu-
litis, PWV and AIx were increased compared to controls,
but only in patients with active disease [59, 60].
Limitation of the study
Five minutes HRV was used to assess the function of the
autonomic nervous system. This method limits the
measurement of vagal predominance during nighttime.
However, other studies assessing patients with PsA have
also obtained 5 min HRV with results comparable to our
findings.
The difference in HRV in the intention to treat and
per-protocol results might be explained by non-
compliance. Compliance and adherence to the study
protocol might have been improved with administration
of more concentrated capsules of n-3 PUFA resulting in
fewer capsules per day for the patients.
Olive oil has often been used as control oil in studies
investigating the effects of fish oil in patients with arth-
ritis but olive oil itself may have some effect on inflam-
mation [61]. However, marine n-3 PUFA have been
shown to be superior to olive oil in several studies of
CVD [37] and olive oil had no anti-arrhythmic effect in
previous studies [62, 63]. The mean intake of monoun-
saturated fat in Denmark is 36 g/d [64] and therefore,
adding 3 g/d of olive oil would not be expected to have
Table 5 Per-protocol analysis
Estimated effect (95% CI) F statistic P N
RR ms 35.26 (3.00 to 67.53) 4.70 0.03 114
PNN50 % 1.81 (−3.99 to 7.61) 0.38 0.54 114
SDNN ms −0.05 (−9.49 to 9.39) 0.00 0.99 114
RMSSD ms 1.35 (−9.06 to 11.76) 0.07 0.80 114
Peripheral systolic BP, mmHg −1.48 (−6.25 to 3.29) 0.38 0.54 117
Peripheral diastolic BP, mmHg 0.26 (−2.45 to 2.96) 0.03 0.85 117
Pulse Wave Velocity, m/s −0.15 (−0.83 to 0.54) 0.18 0.67 111
Central systolic BP mmHg −0.90 (−5.23 to 3.44) 0.17 0.68 117
Central diastolic BP mmHg −1.57 (−4.94 to 1.79) 0.86 0.36 117
PWA AIx 2.91 (0.12 to 5.71) 4.26 0.04 117
ANCOVA analysis of differences in outcomes from baseline to 24 weeks comparing n-3 PUFA to control. Analysis are controlled for age, sex, smoking, diabetes
mellitus, hypertension, blood pressure, hypercholesterolemia, NSAID treatment and Disease activity scores. N are numbers of patients
CI Confidence Interval, HRV Heart rate variability, BP Blood pressure, PWV Pulse wave velocity, AIx central Augmentation Index
Table 4 Per-protocol data with no adjustments
n-3 PUFA (n = 58) Control (n = 56)
Baseline Week 24 Difference (CI) Baseline Week 24 Difference (CI) P
Heart rate 63.24 61.73 −1.51 (−2.89; −0.13) 63.39 64.38 0.98 (−0.54; 2.50) 0.02
RR ms 964.14 990.39 26.25 (6.21; 46.30) 964.02 950.53 −13.48 (−35.66; 8.69) 0.01
PNN50 % 11.39 11.65 0.26 (−4.06; 4.58) 15.83 14.37 −1.46 (−4.76; 1.84) 0.52
SDNN ms 51.56 49.36 −2.20 (−9.96; 5.56) 49.71 47.41 −2.30 (−6.79; 2.20) 0.98
RMSSD ms 39.10 37.85 −1.25 (−9.41; 6.91) 39.84 39.15 −0.69 (−6.23; 4.85) 0.91
Peripheral BP Systolic mmHg 137.67 134.29 −3.38 (−7.03; 0.26) 134.41 133.18 −1.23 (−4.59; 2.14) 0.39
Peripheral BP Diastolic mmHg 81.96 80.88 −1.08 (−2.89; 0.74) 82.36 80.92 −1.44 (−3.26; 0.39) 0.78
PWV m/s 7.66 7.61 −0.04 (−0.51;- 0.43) 7.40 7.48 0.08 (−0.33; 0.49) 0.70
Central BP systolic mmHg 114.62 112.17 −2.44 (−5.17; 0.28) 113.29 111.38 −1.91 (−4.77; 0.95) 0.79
Central BP diastolic mmHg 95.50 93.13 −2.37 (−4.49; −0.24) 95.45 94.17 −1.29 (−3.51; 0.94) 0.49
PWA AIx 26.42 27.51 1.12 (−0.56; 2.80) 27.02 25.84 −1.15 (−2.78; 0.47) 0.06
Outcomes presented as means with 95% confidence intervals at baseline and after 24 weeks of supplement for both groups
CI Confidence Interval, P P for difference between the two groups of supplement, PWV Pulse wave velocity, BP blood pressure, AIx central Augmentation Index
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a substantial effect on the results. Also, we found no sig-
nificant changes in the content in granulocytes of oleic
acid and linoleic acid (main components of olive oil) in
the control group after 24 weeks of supplementation
(Table 2).
Conclusion
In conclusion, our study demonstrated a beneficial effect
of n-3 PUFA on RR and HR in a well-characterized
group of patients with PsA. The results may indicate a
beneficial effect of n-3 PUFA on cardiac autonomic tone
in patients with PsA and further large-scale studies are
needed to demonstrate whether this translates into a re-
duction of CVD in these patients.
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